Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

The OncFive: Top Oncology Articles for the Week of 12/29

January 4th 2025

This week’s top 5 includes a snapshot of FDA approvals from December, an exclusive roundup of critical NCCN guideline updates from 2024, and more.

FDA Grants Priority Review to Avutometinib Plus Defactinib for KRAS+ Recurrent Low-Grade Serous Ovarian Cancer

January 2nd 2025

The FDA has granted priority review to the NDA for avutometinib plus defactinib in KRAS-mutant recurrent low-grade serous ovarian cancer.

OncLive’s December Roundup of Key FDA Approvals in Oncology

December 30th 2024

Here is your snapshot of all therapeutic options greenlit by the FDA in December 2024 spanning tumor types.

Allosteric Inhibitors Targeting PIK3CA May Reduce Treatment Toxicities in Breast Cancer

December 26th 2024

Felipe Batalini, MD, and Alberto Montero, MD, MBA, CPHQ, detail how allosteric inhibitors targeting PIK3CA such as STX-478 may reduce toxicities seen with orthosteric inhibitors.

The OncFive: Top Oncology Articles for the Week of 12/15

December 21st 2024

The FDA awards accelerated approval to encorafenib regimen in BRAF V600E+ CRC, ensartinib wins approval in ALK+ non–small cell lung cancer, and more.

FDA Grants Accelerated Approval to Encorafenib Plus Cetuximab and Chemo for BRAF V600E+ Metastatic Colorectal Cancer

December 20th 2024

The FDA has approved encorafenib plus cetuximab and mFOLFOX6 for metastatic colorectal cancer with a BRAF V600E mutation.

Dr Wang on Ziftomenib Plus Intensive Induction in Newly Diagnosed, NPM1+ or KMT2A+ AML

December 10th 2024

Eunice S. Wang, MD, on ziftomenib plus intensive induction in newly diagnosed, NPM1-mutated or KMT2A-rearranged acute myeloid leukemia.

Dr Kaddoura on Genomic Determinants of Outcomes in IGH/CCND1+ Myeloma Treated With Venetoclax

December 8th 2024

Marcella Ali Kaddoura, MD, discusses genomic determinants of clinical outcomes in myeloma with t(11;14)(CCND1;IGH) treated with venetoclax.

Targeting PIK3CA With Allosteric Inhibitors Is Promising New Approach in Breast Cancer

December 6th 2024

Felipe Batalini, MD, details how targeting PIK3CA is evolving in breast cancer as new allosteric inhibitors have emerged and showed promising safety/efficacy.

FDA Grants Accelerated Approval to Zenocutuzumab for NRG1+ NSCLC and Pancreatic Adenocarcinoma

December 4th 2024

The FDA granted accelerated approval to zenocutuzumab for select patients with NSCLC and pancreatic adenocarcinoma with NRG1 fusions.

NGS and Novel Therapies Lends to Prolonged Survival Outcomes in HR+/ HER2– Breast Cancer

December 4th 2024

Francisco J. Esteva, MD, PhD, discusses how NGS sequencing, PIK3CA-targeted therapies, and ADCs are reshaping treatment in HR+/HER2– breast cancer.

OncLive’s November Roundup of Key FDA Approvals in Oncology

December 3rd 2024

Here is your snapshot of all treatment options that the FDA cleared in November 2024 spanning tumor types.

Revisit Every OncLive On Air Episode From November 2024

December 2nd 2024

In case you missed any, read a recap of every episode of OncLive On Air that aired in November 2024.

Eflornithine Plus Lomustine Demonstrates Clinically Meaningful Survival Benefits in Grade III IDH-Mutant Astrocytoma

December 2nd 2024

Rimas V. Lukas, MD, discusses the potential role for eflornithine plus lomustine in recurrent grade 3 IDH-mutant astrocytoma.

Overcoming Challenges With Molecular Testing in NSCLC, Other Solid Tumors

November 26th 2024

Mary B. Beasley, MD, discusses molecular testing challenges in non–small cell lung cancer and pancreatic cancer.

Using a Multidisciplinary Approach in NRG1+ NSCLC, Pancreatic Cancer

November 26th 2024

Mary B. Beasley, MD, discusses the multidisciplinary management of NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.

The Pathologist’s Role in Molecular Testing in NSCLC, Pancreatic Cancer

November 26th 2024

Mary B. Beasley, MD, discusses the role of pathologists in molecular testing in non–small cell lung cancer and pancreatic cancer.

The Role of RNA in Detecting NRG1 and Other Fusions in Solid Tumors

November 26th 2024

Mary B. Beasley, MD, discusses the role of RNA and other testing considerations for detecting NRG1 and other fusions in solid tumors.

Harnessing the Ability to Target NRG1 Fusions in NSCLC, Pancreatic Cancer

November 26th 2024

Mary B. Beasley, MD, discusses the prevalence of NRG1 fusions in non–small cell lung cancer and pancreatic cancer.

Perioperative Vorasidenib and Ivosidenib Remain Effective, Safe in IDH1+ Diffuse Glioma

November 25th 2024

Perioperative vorasidenib or ivosidenib demonstrated sustained clinical benefit in patients with predominantly non-enhancing IDH1-mutant diffuse glioma.